TNPSC Thervupettagam
July 13 , 2020 1472 days 801 0
  • The Drug Controller General of India (DCGI) has given its approval to ‘Itolizumab’ injection.
  • It is for the treatment of COVID-19 patients with restricted emergency use only in case of moderate to severe Acute Respiratory Distress Syndrome (ARDS) patients.
  • Bengaluru based biopharmaceutical company - Biocon Limited is the developer and the manufactures of the Itolizumab injection.

Leave a Reply

Your Comment is awaiting moderation.

Your email address will not be published. Required fields are marked *

Categories